BioSig Expands its Installation Base in Texas
November 04 2021 - 11:00AM
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the
"Company"), a medical technology company commercializing an
innovative signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced the Company is installing a PURE EP(tm)
System for an evaluation at the Methodist Hospital in San Antonio,
TX, one of the largest hospitals in the United States in terms of
the number of available beds. This 90-day evaluation agreement
brings the Company up to 15 installed centers. “Texas is one of the
three strategic areas that we are focusing on in the targeted
commercial launch phase, and we are very pleased to welcome another
Texas center to our customer base. Methodist Hospital conducted
over 1800 cardiac ablations last year, and some of our greatest
accomplishments have been achieved at similarly high-volume
centers. We look forward to bringing our technology to more
physicians in Texas to advance our clinical and commercial
strategies further,” commented Kenneth L. Londoner, Chairman, and
CEO of BioSig Technologies, Inc.
To date, over 71 physicians have completed over 1600 patient
cases with the PURE EP(tm) System across thirteen clinical sites.
The Company is in a focused commercial launch of the PURE EP(tm)
System in the Northeast, Texas, and Florida, and the technology is
in regular use in some of the country’s leading centers of
excellence, including the Mayo Clinic in Rochester, MN, and St.
David’s Medical Center in Austin, TX.
Clinical data acquired by the PURE EP(tm) System in a
multi-center study at Texas Cardiac Arrhythmia Institute at St.
David’s Medical Center, Mayo Clinic Jacksonville and Massachusetts
General Hospital was recently published in the Journal of
Cardiovascular Electrophysiology and is available electronically
with open access via the Wiley Online Library. Study results showed
93% consensus across the blinded reviewers with a 75% overall
improvement in intracardiac signal quality and confidence in
interpreting PURE EP(tm) signals over conventional sources.
One in 18 Americans suffers from a cardiac arrhythmia. Atrial
fibrillation is the most common arrhythmia type, affecting over 33
million people worldwide, including over 6 million in the U.S. The
number of people suffering from atrial fibrillation is expected to
reach 8-12 million by 20501. According to the Centers for
Disease Control and Prevention (CDC), atrial fibrillation causes
more than 750,000 hospitalizations in the U.S. each year, resulting
in approximately $6 billion in healthcare spending annually2.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EP(tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording, and
storing electrocardiographic and intracardiac signals for patients
undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) the geographic, social and
economic impact of COVID-19 on our ability to conduct our business
and raise capital in the future when needed, (ii) our inability to
manufacture our products and product candidates on a commercial
scale on our own, or in collaboration with third parties; (iii)
difficulties in obtaining financing on commercially reasonable
terms; (iv) changes in the size and nature of our competition; (v)
loss of one or more key executives or scientists; and (vi)
difficulties in securing regulatory approval to market our products
and product candidates. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s website at
http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new
information, future events or otherwise.
1 Top 10 Things You should Know About Heart Rhythm; Scripps
Health.
2 Managing Atrial Fibrillation; Lisa Eramom MA, Medical
Economics Journal, February 25, 2019, Volume 96, Issue 4
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms Road
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jun 2024 to Jul 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jul 2023 to Jul 2024